Scarica l'app Stockscreener
18.92
5.21%
-1.04
Precedente Chiudi:
$19.96
Aprire:
$20.17
Volume 24 ore:
1.45M
Relative Volume:
0.91
Capitalizzazione di mercato:
$2.34B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-6.123
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-10.03%
1M Prestazione:
-16.80%
6M Prestazione:
+88.07%
1 anno Prestazione:
+48.98%
Intervallo 1D:
$18.81
$20.53
Intervallo di 1 settimana:
$18.81
$21.58
Portata 52W:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
18.92 | 2.47B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
What’s Arcus Biosciences Inc.’s historical returnJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - mfd.ru
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
How cyclical is Arcus Biosciences Inc.’s revenue streamWeekly Trade Report & High Return Trade Opportunity Guides - mfd.ru
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Is Arcus Biosciences Inc. stock a smart retirement pickJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know - TipRanks
Arcus Biosciences stock hits 52-week high at $21.03 By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week high at $21.03 - Investing.com
Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen - MarketBeat
(RCUS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - sharewise.com
Aug Decliners: How correlated is Arcus Biosciences Inc to the S P500Portfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews
What is Arcus Biosciences Inc.’s valuation compared to sectorTrend Reversal & Capital Efficient Trade Techniques - mfd.ru
Arcus Biosciences Grants Stock Options to Employees - intellectia.ai
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Bear Alert: How does Arcus Biosciences Inc score in quality rankingsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
New Arcus Biosciences hires get 16,650 options plus RSUs - Stock Titan
Responsive Playbooks and the RCUS Inflection - Stock Traders Daily
Market Review: Can Arcus Biosciences Inc be recession proofWeekly Risk Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-01-23 23:49:02 - baoquankhu1.vn
Arcus Biosciences (RCUS): Investor Outlook Reveals 43% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
EPS Watch: How correlated is Arcus Biosciences Inc to the S P5002025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Will Arcus Biosciences Inc. stock recover faster than marketPortfolio Risk Assessment & Free Daily Top Stock Picks for All Investors - bollywoodhelpline.com
Arcus Biosciences, Inc. (NYSE:RCUS) Sees Significant Increase in Short Interest - MarketBeat
Arcus Biosciences (NYSE:RCUS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Reveals a 51.45% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Bank of America Securities Keeps Their Hold Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences appoints new Chief Medical Officer - MSN
Arcus Biosciences (NYSE:RCUS) Trading Down 5.8%Time to Sell? - MarketBeat
Is Arcus Biosciences (RCUS) Using Casdatifan to Quietly Redefine Its Core Oncology Strategy? - Sahm
Goldman Sachs Upgrades Arcus Biosciences (RCUS) to 'Buy', Raises Price Target | RCUS Stock News - GuruFocus
Goldman Sachs Upgrades Arcus Biosciences (RCUS) - Nasdaq
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage - TechStock²
Arcus Biosciences (NYSE:RCUS) Shares Gap UpHere's What Happened - MarketBeat
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating - Investing.com India
Risk Check: What is Arcus Biosciences Incs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Arcus downgraded at Morgan Stanley on balanced risk-reward setup - MSN
Arcus Biosciences (RCUS) Valuation Check After Recent Share Price Pullback And 1 Year Gain - Yahoo Finance
Los Angeles Daily NewsArcus Biosciences, Inc. Common Stock (NYSE:RCUS) Stock Quote - FinancialContent
Wall Street Zen Downgrades Arcus Biosciences (NYSE:RCUS) to Sell - MarketBeat
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - Улправда
Arcus Biosciences (RCUS) CEO Terry Rosen donates 35,000 shares in Form 4 - Stock Titan
Arcus Biosciences, Inc. (RCUS) Investor Outlook: Exploring A 48.95% Upside Potential - DirectorsTalk Interviews
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):